Biallelic mutations in KDSR disrupt ceramide synthesis and result in a spectrum of keratinization disorders associated with thrombocytopenia by Takeichi, Takuya et al.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
King’s Research Portal 
 
DOI:
10.1016/j.jid.2017.06.028
Document Version
Peer reviewed version
Link to publication record in King's Research Portal
Citation for published version (APA):
Takeichi, T., Torrelo, A., Lee, J. Y. W., Ohno, Y., Lozano, M. L., Kihara, A., ... McGrath, J. A. (2017). Biallelic
mutations in KDSR disrupt ceramide synthesis and result in a spectrum of keratinization disorders associated
with thrombocytopenia. Journal of Investigative Dermatology, 137(11), 2344-2353.
https://doi.org/10.1016/j.jid.2017.06.028
Citing this paper
Please note that where the full-text provided on King's Research Portal is the Author Accepted Manuscript or Post-Print version this may
differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version for pagination,
volume/issue, and date of publication details. And where the final published version is provided on the Research Portal, if citing you are
again advised to check the publisher's website for any subsequent corrections.
General rights
Copyright and moral rights for the publications made accessible in the Research Portal are retained by the authors and/or other copyright
owners and it is a condition of accessing publications that users recognize and abide by the legal requirements associated with these rights.
•Users may download and print one copy of any publication from the Research Portal for the purpose of private study or research.
•You may not further distribute the material or use it for any profit-making activity or commercial gain
•You may freely distribute the URL identifying the publication in the Research Portal
Take down policy
If you believe that this document breaches copyright please contact librarypure@kcl.ac.uk providing details, and we will remove access to
the work immediately and investigate your claim.
Download date: 05. Apr. 2019
Accepted Manuscript
Biallelic mutations in KDSR disrupt ceramide synthesis and result in a spectrum of
keratinization disorders associated with thrombocytopenia
Takuya Takeichi, Antonio Torrelo, John Y.W. Lee, Yusuke Ohno, María Luisa Lozano,
Akio Kihara, Lu Liu, Yuka Yasuda, Junko Ishikawa, Takatoshi Murase, Ana Belén
Rodrigo, Pablo Fernández-Crehuet, Yoichiro Toi, Jemima Mellerio, José Rivera,
Vicente Vicente, David P. Kelsell, Yutaka Nishimura, Yusuke Okuno, Daiei Kojima,
Yasushi Ogawa, Kazumitsu Sugiura, Michael A. Simpson, W. H. Irwin McLean,
Masashi Akiyama, John A. McGrath
PII: S0022-202X(17)32733-1
DOI: 10.1016/j.jid.2017.06.028
Reference: JID 987
To appear in: The Journal of Investigative Dermatology
Received Date: 20 May 2017
Revised Date: 24 June 2017
Accepted Date: 28 June 2017
Please cite this article as: Takeichi T, Torrelo A, Lee JYW, Ohno Y, Lozano ML, Kihara A, Liu L, Yasuda
Y, Ishikawa J, Murase T, Rodrigo AB, Fernández-Crehuet P, Toi Y, Mellerio J, Rivera J, Vicente V,
Kelsell DP, Nishimura Y, Okuno Y, Kojima D, Ogawa Y, Sugiura K, Simpson MA, McLean WHI, Akiyama
M, McGrath JA, Biallelic mutations in KDSR disrupt ceramide synthesis and result in a spectrum of
keratinization disorders associated with thrombocytopenia, The Journal of Investigative Dermatology
(2017), doi: 10.1016/j.jid.2017.06.028.
This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to
our customers we are providing this early version of the manuscript. The manuscript will undergo
copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please
note that during the production process errors may be discovered which could affect the content, and all
legal disclaimers that apply to the journal pertain.
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
1 
 
Accepted version 
 
Biallelic mutations in KDSR disrupt ceramide synthesis and result in a 
spectrum of keratinization disorders associated with thrombocytopenia 
 
Takuya Takeichi
1,2
, Antonio Torrelo
3
, John Y. W. Lee
1
, Yusuke Ohno
4
, María Luisa Lozano
5
, 
Akio Kihara
4
, Lu Liu
6
, Yuka Yasuda
7
, Junko Ishikawa
8
, Takatoshi Murase
8
, Ana Belén Rodrigo
9
, 
Pablo Fernández-Crehuet
10
, Yoichiro Toi
11
, Jemima Mellerio
1,12
, José Rivera
5
, Vicente 
Vicente
5
, David P. Kelsell
13
, Yutaka Nishimura
14
, Yusuke Okuno
15,16
, Daiei Kojima
16
, Yasushi 
Ogawa
2
, Kazumitsu Sugiura
17
, Michael A. Simpson
18
, W. H. Irwin McLean
19
, Masashi 
Akiyama
2
, John A. McGrath
1,19
 
 
1. St John’s Institute of Dermatology, King’s College London (Guy’s Campus), London, UK 
2. Department of Dermatology, Nagoya University Graduate School of Medicine, Nagoya, 
Japan 
3. Department of Dermatology, Hospital Infantil del Niño Jesús, Madrid, Spain 
4. Faculty of Pharmaceutical Sciences, Hokkaido University, Sapporo, Japan 
5. Centro Regional de Hemodonación, Servicio de Hematología y Oncología Médica, 
Hospital Universitario Morales Meseguer, IMIB-Arrixaca, Universidad de Murcia.Centro 
de Investigación Biomédica en Red de Enfermedades Raras (CIBERER, CB15/00055), 
Instituto de Salud Carlos III (ISCIII) Madrid, Spain 
6. Viapath, St Thomas’ Hospital, London, UK 
7. Analytical Science Research Laboratories, Kao Corporation, Haga, Tochigi, Japan 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
2 
 
8. Biological Science Research Laboratories, Kao Corporation, Haga, Tochigi, Japan 
9. Department of Dermatology, Hospital Sierra de Segura, Puente de Génave, Jaén, Spain 
10. Department of Dermatology, Hospital Universitario Reina Sofía, Córdoba, Spain 
11. Department of Dermatology, Hiroshima City Hiroshima Citizens Hospital, Hiroshima, 
Japan 
12. Department of Dermatology, Great Ormond Street Hospital for Children NHS Foundation 
Trust, London, United Kingdom 
13. Centre for Cell Biology and Cutaneous Research, Blizard Institute, Barts and the London 
School of Medicine and Dentistry, Queen Mary University of London, Whitechapel, 
London, UK 
14. Department of General Perinatology, Hiroshima City Hiroshima Citizens Hospital, 
Hiroshima, Japan 
15. Center for Advanced Medicine and Clinical Research, Nagoya University Hospital, 
Nagoya, Japan 
16. Department of Pediatrics, Nagoya University Graduate School of Medicine, Nagoya, 
Japan 
17. Department of Dermatology, Fujita Health University School of Medicine, Toyoake, 
Japan 
18. Department of Medical and Molecular Genetics, King’s College London, School of 
Medicine, Guy’s Hospital, London, UK 
19. Centre for Dermatology and Genetic Medicine, Division of Molecular Medicine, 
University of Dundee, Dundee, UK 
 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
3 
 
Corresponding author: John A. McGrath, Dermatology Research Labs, Floor 9 Tower Wing, 
Guy’s Hospital, Great Maze Pond, London SE1 9RT, United Kingdom. Tel: 44-2071886409; 
Fax: 44-2071888050; E-mail: john.mcgrath@kcl.ac.uk 
 
Short title: KDSR mutations disrupt skin and platelet function 
 
Keywords: Keratoderma, ichthyosis, thrombocytopenia, KDSR, ceramide. 
 
Abbreviations: KDSR, 3-ketodihydrosphingosine reductase; WES, whole-exome sequencing. 
  
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
4 
 
 
ABSTRACT 
 
Mutations in ceramide biosynthesis pathways have been implicated in a few Mendelian 
disorders of keratinization although ceramides are known to have key roles in several 
biological processes in skin and other tissues. Using whole-exome sequencing in four 
probands with undiagnosed skin hyperkeratosis/ichthyosis, we identified compound 
heterozygosity for mutations in KDSR, encoding an enzyme in the de novo synthesis 
pathway of ceramides. Two individuals had hyperkeratosis confined to palms and soles as 
well as anogenital skin, whereas the other two had more severe, generalized harlequin 
ichthyosis-like skin. Of note, thrombocytopenia was present in all cases. The mutations in 
KDSR were associated with reduced ceramide levels in skin and impaired platelet function. 
KDSR enzymatic activity was variably reduced in all cases resulting in defective acylceramide 
synthesis. Mutations in KDSR have recently been reported in inherited recessive forms of 
progressive symmetric erythrokeratoderma, but our study demonstrates that biallelic 
mutations in KDSR are implicated in an extended spectrum of disorders of keratinization in 
which thrombocytopenia is also part of the phenotype. Mutations in KDSR cause defective 
ceramide biosynthesis, underscoring the importance of ceramide and sphingosine synthesis 
pathways in skin and platelet biology. 
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INTRODUCTION 
The hereditary palmoplantar keratodermas and ichthyoses comprise a 
heterogeneous collection of genodermatoses caused by mutations in >100 genes involved in 
a multitude of biologic pathways and processes (Oji et al., 2010; Sakiyama and Kubo, 2016). 
Despite major advances in discovering the underlying molecular genetic basis of many of 
these disorders, several cases remain unresolved, indicating the likely contribution of 
further gene pathology (Fischer, 2009).  
One very recent discovery that expands the molecular pathology of ichthyosis has 
been the identification of mutations in KDSR in four individuals with clinical phenotypes of 
progressive symmetric erythrokeratoderma (PSEK) (Boyden et al., 2017). KDSR encodes 3-
ketodihydrosphingosine reductase which catalyzes the reduction of 3-
ketodihydrosphingosine (KDS) to dihydrosphingosine (DHS), a key step in the de novo 
ceramide synthesis pathway (Linn et al., 2001). Previously, mutations in a different gene in 
this pathway, CERS3 (ceramide synthase 3), have also been implicated in autosomal 
recessive congenital ichthyosis (ARCI), emphasizing the clinical relevance of ceramide 
pathology in inherited disorders of cornification (Radner et al., 2013; Eckl et al., 2013). 
Ceramides also have key physiological roles in other organs: mutations in ELOVL4, encoding 
an enzyme necessary for the production of ultra long chain ceramides in the skin, brain and 
retina, lead to a recessive disorder characterized by ichthyosis, intellectual disability and 
spastic quadriplegia (Aldahmesh et al., 2011). 
In this study, we investigated four individuals from Spain, Japan and the United 
Kingdom who presented with inherited disorders of keratinization, but with different clinical 
features to those presented by Boyden et al. (2017). Notably, two patients displayed a 
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milder phenotype of palmoplantar and anogenital hyperkeratosis, whereas the other two 
cases had a more severe phenotype resembling harlequin ichthyosis. An additional finding, 
present in all our subjects, but not featured in the Boyden et al. (2017) study, was a 
reduction in the number of blood platelets (thrombocytopenia). 
Using whole-exome sequencing, functional studies on skin and platelets, as well as in 
vitro analyses, we identified autosomal recessive mutations in KDSR in all 4 subjects, with 
only one heterozygous mutation overlapping with published findings (Boyden et al., 2017). 
Our findings expand the molecular and clinical pathology associated with KDSR mutations 
and demonstrate that this ceramide biosynthesis pathway has important roles in both skin 
and platelets. 
 
RESULTS 
Clinical features of individuals with KDSR mutations 
Permission to report medical details and include clinical illustrations was obtained 
for all patients (guardians for patients 1, 3 and 4; and from patient 2, himself). 
Patient 1 is a 15-year-old male and the only child of unrelated healthy parents 
(Family 1; see Figure 1a). His parents are originally from the same geographic area in mid-
southeast Spain. Since the age of 12 months, he developed palmoplantar hyperkeratosis 
with extension to the dorsae of the hands and feet, wrists and ankles, as well as anogenital 
hyperkeratosis and erythema (Figure 2a-c). Aged 2 years, a blood count was performed 
because of mucocutaneous bleeding, which revealed a severe, isolated thrombocytopenia 
(platelets <30x10
9
/L; bone marrow biopsy showed a normal to increased number of 
megakaryocytes only). A diagnosis of primary immune thrombocytopenia was made but 
treatment with oral corticosteroids was suboptimal. Splenectomy aged 11 years led to a 
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slight increase in platelets (~40x10
9
/L) although clinically he continues to suffer recurrent 
nose bleeds. Light microscopy of lesional skin revealed non-specific findings of psoriasiform 
acanthosis, parakeratosis and focal hypergranulosis but no epidermolytic changes (Figure 
2d-e). Oral acitretin (0.5mg/kg) prescribed for several months did not lead to any 
improvement in his skin. 
Patient 2 is a 21-year-old male and the older of two brothers born to healthy 
unrelated parents (Family 2; Figure 1b). He is the only affected individual among his 
relatives. This family originates from the same geographic region in Spain as Family 1. Aged 
15 months, he developed diffuse hyperkeratosis on the palms and soles, without 
progression to the dorsae of hands or feet (i.e. less severe than Patient 1). He also 
developed perianal erythema and hyperkeratosis. As for patient 1, oral acitretin did not 
improve the hyperkeratosis. In addition, he suffered episodes of bruising with evidence of 
isolated thrombocytopenia. Bone marrow studies showed normal hematologic morphology. 
At present, he has not manifested clinically relevant signs of bleeding despite persistently 
low platelets (~20x10
9
/L).  
Patient 3 was the second child born to unrelated white Caucasian parents from the 
United Kingdom (Family 3; Figure 1c). His parents, older brother, and all other relatives were 
healthy. His mother’s pregnancy was uneventful until the last trimester when 
oligohydramnios was noted. She had spontaneous rupture of membranes at 33+5 weeks 
and underwent elective cesarean section at 35+2 weeks with an infant birth weight of 2.74 
kg. At birth, the patient was covered in thick adherent plate-like scales with prominent 
ectropion and eclabium, and pinching of all digits, collectively consistent with harlequin 
ichthyosis. He was treated in a humidified incubator with hourly greasy emollients and 
lubricating eye drops. Acitretin was started which led to some reduction in adherent scaling, 
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although he developed pseudomonas septicemia aged 15 days and further sepsis thereafter. 
At birth, platelet count was 120x10
9
/L but within 2 weeks this dropped to 50x10
9
/L, and by 
the 3
rd
 week to ~20-30x10
9
/L and remained at this level. At day 36, he deteriorated clinically 
with tachypnea and hypotension associated with a profound metabolic acidosis. Despite 
efforts to resuscitate him, he died aged 37 days. 
Patient 4 is a 6-year-old Japanese male and is the younger of two brothers born to 
unrelated parents (Family 4; Figure 1d). His mother and brother have atopic dermatitis, but 
there is no other noteworthy family history. He was delivered at 35+3 weeks by normal 
spontaneous vaginal delivery with a birth weight of 1.9 kg. At birth, he had thick plate-like 
scales with deep fissuring overlying erythrodermic skin. Severe eclabium and ectropion were 
also observed. Skin biopsy revealed marked hyperkeratosis with parakeratosis 
(Supplementary Figure S1 online). These features were consistent with Harlequin ichthyosis. 
He was treated in the neonatal intensive care unit but did not receive systemic retinoids. 
Over the first 2 months of life, the thick scales desquamated gradually, resulting in 
generalized erythroderma and fine scaling. Platelet count was normal at birth (140-
150x10
9
/L) but since the age of 2 months this progressively decreased, and at 3 years of age 
he had severe thrombocytopenia (4-11x10
9
/L).  
 
Identification of compound heterozygous mutations in KDSR in all affected individuals 
After ethics’ committee approval and written informed consent, whole-exome 
sequencing (WES) was performed using DNA from all affected probands. Candidate gene 
mutations were prioritized by filtering for variants with a frequency of less than 0.1% in 
public databases such as the Exome Aggregation Consortium (ExAC), Exome Variant Server 
(EVS), 1000 Genomes Project and an in-house repository. Of note, WES revealed compound 
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heterozygous mutations in KDSR, a candidate gene recently implicated in progressive 
symmetric erythrokeratoderma (Boyden et al., 2017). Details of the mutations are shown in 
Figure 1e and Table 1; only one of the heterozygous mutant alleles overlapped with the 
known KDSR mutations. The mutations were verified by Sanger sequencing (Supplementary 
Figure S2 online) and segregated with disease status in family members whose DNA was 
available (Figures 1a-d). Our study revealed three missense mutations (p.Phe138Cys; 
p.Gly182Ser; p.Gly271Glu), one synonymous variant (c.879G>A, p.Gln293Gln, but affecting 
the last base of an exon and therefore potentially a donor splice site mutation), one other 
splice site mutation (c.417+3G>A), and one out-of-frame deletion (c.223_224delGA, 
p.Glu75Asnfs*2) (Figure 1e). Patients 1 and 2 come from the same region of Spain and 
therefore, although neither family was aware of any relatedness, the finding of identical 
compound heterozygotes mutations in KDSR (p.Phe138Cys and c.417+3G>A), is likely to 
indicate sharing of regional founder mutations. The splicing mutation (c.417+3A>C) was 
predicted to cause a reduction of 41.8% of transcripts expressing exon 5 of KDSR, based on 
the SPANR tool (Xiong et al., 2015), which was confirmed by RT-PCR using RNA extracted 
from skin (Patients 1 and 2). Sequencing of cDNA from exon 2 to exon 7 of KDSR 
demonstrated skipping of exon 5 (96-bp, Δ5) or skipping of exons 5 and 6 (288-bp, Δ5Δ6) 
(Supplementary Figure S3a, b online). Both of these truncated transcripts restore the 
reading frames. Using cDNA from peripheral blood, in-frame skipping of exon 5 was 
demonstrated (Supplementary Figure S3c online). The synonymous c.879G>A mutation 
(p.Gln293Gln) was previously identified in the study by Boyden et al. (2017). This nucleotide 
transition occurs within the last base of exon 9 and RT-PCR in that report showed in-frame 
skipping of exon 9.   
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KDSR mutations impair enzymatic activity and lead to defective acylceramide synthesis 
To assess the effect of the mutations on KDSR enzymatic activity, the new mutations 
identified in our patients were introduced into yeast and HEK 293T cells. Two mutant 
plasmids were designed for the c.417+3A>C variant, one predicting skipping of exon 5 only 
(Δ5) and the other loss of both exons 5 and 6 (Δ5Δ6) (Figure 3a). Primer details for the 
mutant constructs are shown in Supplementary Table S1 online. 
A yeast complementation assay was performed using yeast grown on plates with or 
without phytosphingosine (PHS). Because sphingolipids are essential for cell viability, Δtsc10 
yeast cells cannot grow normally unless the addition of PHS or dihydrosphingosine (DHS) to 
the medium bypasses the requirement of de novo sphingolipid synthesis. Therefore, under 
these circumstances, yeast would not be able to grow normally if the KDSR mutants impair 
enzymatic activity. This assay revealed that the mutations (illustrated for Patients 1, 2 and 3; 
Figure 3b) diminished the ability of yeast to grow in the absence of PHS, similar to the three 
different mutations tested by Boyden et al. (2017). The p.Phe138Cys mutant had the mildest 
effect. In comparison, the Δ5 and Δ5Δ6 mutants (representing the c.417+3A>C mutation) 
resulted in the most significant impairment of yeast growth (Figure 3b). 
To assess the enzymatic activity in vitro, all mutant constructs (including those for 
patient 4, performed separately under similar conditions) were introduced into HEK 293T 
cells (Figure 3c) and KSDR activity was measured in vitro using membrane fractions, 
notwithstanding an inherent limitation of this assay being that HEK 293T cells have 
endogenous KDSR activity, which is not abolished. Consistent with the yeast 
complementation assay, this revealed that most of the mutants led to a significant 
reduction in DHS synthesis (Figure 3d). The only exception was the p.Gly182Ser (c.544G>A) 
variant, which showed no significant difference in DHS synthesis compared to wild-type 
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(Figure 3d). The p.Gly182Ser mutation occurs within the hydrophilic domain (amino acids 
22-270), similar to two mutations found by Boyden et al. (2017), and close to the canonical 
TyrXXXLys reductase site (amino acids 186-190). By analogy with the Boyden et al. (2017) 
data, p.Gly182Ser is likely to lead to a structural protein change, rather than impacting on 
glycosylation or phosphorylation.  
 
KDSR expression and ceramide immunolabeling are reduced in patient skin 
Quantitative PCR (qPCR) was performed using whole skin RNA from Patient 1, 
Patient 2 and four healthy individuals (data shown in Supplementary Figure S4 online; probe 
details in Table S2 online). KDSR expression was found to be reduced in both affected 
individuals, but not dramatically (70-80% of control; Figure S4a). Of note, expression of FLG, 
CERS3, IVL, KRT10 and KRT14 was increased in both patients (Figure S4b-f). 
Immunofluorescence staining was performed on skin sections from Patient 1, Patient 2 and 
a control individual to examine changes in protein levels or localization. KDSR labeling was 
not visibly reduced in patient skin (Supplementary Figure S5 online; antibody details in Table 
S3 online). Staining with an anti-ceramide antibody revealed reduced (but not absent) 
ceramide levels in patient skin, supporting the hypothesis that KDSR mutations lead to 
dysregulation of ceramide biosynthesis, although the broad reactivity of the antibody (which 
recognizes ceramide-2, ceramide-3, ceramide-5, ceramide C14, ceramide C16, dihydro-
ceramide C16, but not sphingosine or dihydro-sphingosine) limits further interpretation. In 
keeping with the gene expression changes observed, immunoreactivity of CERS3, filaggrin 
and loricin was increased in both patients (Figure S5). Taken together, these alterations 
suggest that reduction of KDSR activity leads to diminished levels of ceramide in skin with 
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increased or precocious expression of terminal differentiation markers such as keratin 10, 
involucrin, filaggrin and loricrin. 
 
KDSR mutations lead to variable alterations in skin ceramides  
The levels of 11 major ceramide species in the skin of the forearm, wrist and palm 
were assessed by tape stripping and liquid chromatography-mass spectrometry analysis (see 
Figure 4, as well as Supplementary Tables S4 and S5 online for full details). In the forearms 
of Patients 1 and 2 (uninvolved skin), there was no significant difference in the total 
ceramide, ceramide components or average carbon numbers between the affected 
individuals and their unaffected mothers (Supplementary Table S1 online). In contrast, in 
the affected wrist skin, the levels of total ceramide, CER[EOS], CER[EOH], CER[NP], CER[NH] 
and CER[NS], were reduced in the patients’ samples. Additionally, the average carbon 
numbers of ceramides indicated that short-chain ceramides, CER[NDS], CER[NS] and CER[AS], 
were relatively increased in the patients’ skin. However, due to the small number of samples, 
statistical analyses could not be performed. Likewise, in the affected palm skin samples, the 
levels of total ceramide were decreased in Patient 1 compared to his mother. In contrast, 
there was no difference in the levels of total or individual ceramides between Patient 2 and 
his mother. This discrepancy may be explained by the milder phenotype in Patient 2 
compared to Patient 1. The average carbon numbers of ceramides showed that short-chain 
ceramides, CER[NDS], CER[NS], CER[NP], CER[ADS], CER[AS] and CER[AP], were relatively 
increased in both patients’ palm. Of note, there was a relative (but not absolute) increase of 
short chain ceramides in wrist and palm. Since total ceramide levels decrease, it is more 
likely that overall there is a decrease in longer ceramides. KDSR is one of the key enzymes 
involved in the de novo pathway of sphingolipid synthesis, acting between serine palmitoyl 
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transferase (SPT) and CERS. Therefore, KDSR deficiency may affect this cascade and lead to a 
reduction in the levels of synthesis of total and downstream products.  
 
KDSR mutations reduce platelet number and function 
Detailed analysis of platelets was performed in Patients 1 and 2, their respective 
mothers and healthy controls. No morphologic abnormalities in platelets were noted 
(Supplementary Figure S6 online) although flow cytometry evaluation of platelet volume 
was slightly increased in the patients (Table 2). The patients’ platelets expressed normal 
levels of adhesive surface glycoproteins, but a lower level of phophatidylserine exposure in 
terms of basal annexin V binding positive percentages and also reduced thromboplastin 
expression in unstimulated washed platelets (Table 2). Next, we performed platelet function 
analysis by evaluating granule release and the conformational change of αIIbβ3 integrin 
(CD62P and PAC-1, respectively) upon stimulation with different platelet agonists (Figure 5). 
The increment both in CD62P and PAC-1 positive platelets was lower in patients than in 
controls, specifically with agonists that are known to activate pathways that are highly 
dependent on Src family kinases, such as thrombin (PAR1p and PAR4p), collagen (collagen 
related peptide [CRP]), and adenosine diphosphate (ADP), but not as evident following 
arachidonic acid (AA) stimulation (Figure 5). 
The plasma sphingosine-1-phosphate (S1P) concentration in Patient 1, who 
presented with more severe clinical bleeding, was decreased by 61% compared to controls, 
while the equivalent measure in Patient 2 was reduced by 45% (Figure 6a). The observation 
that serum S1P levels compared to controls were diminished in both patients by only 45% 
and 36%, respectively, suggests that erythrocytes contribute to most of the S1P being 
released in patient samples during blood clotting. Surface-exposed ceramide in human 
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platelets were investigated with an antibody recognizing C24:0 ceramide levels, the 
predominant form of ceramide present in human platelets (Chen et al., 2013). This antibody 
detected a significant increase in ceramide levels in the plasma membrane of controls and 
carriers of the c.417+3A>C mutation following platelet activation, whereas the intensity of 
immunostaining was not changed significantly in affected patients (Figure 6b). 
 
DISCUSSION 
 
In this study, we identified biallelic mutations in KDSR in patients with defective 
keratinization and thrombocytopenia, implicating KDSR in the pathobiology of hereditary 
palmoplantar keratodermas and ichthyosis, as recently demonstrated by Boyden et al. 
(2017), but also demonstrating that KDSR has an important additional role in platelet 
biology. Our data suggest that mutations in KDSR impair ceramide biosynthesis pathways 
and function in skin and platelets.  
Clinically, the skin phenotypes in our patients were diverse – two patients had 
localized hyperkeratosis/keratoderma and the other two had generalized harlequin-like 
ichthyosis. Of note, neither of these forms of abnormal cornification resembled the 
progressive symmetric erythrokeratoderma reported in association with KDSR mutations by 
Boyden et al. (2017). Collectively, most of the mutations are loss-of-function but, at present, 
there does not appear to be a basis for clear genotype-phenotype correlation. 
Prior to the discovery of human mutations in KDSR, data linking this gene to disease 
have been very limited, aside from a missense variant in the bovine ortholog of KDSR that 
was proposed to cause spinal muscular atrophy (Krebs et al., 2007). Intriguingly, however, a 
de novo deletion of human chromosome 18q has been reported previously in an infant with 
lethal harlequin ichthyosis (Stewart et al., 2001): this child’s karyotype was 
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46,XY,del(18)(q21.3). The authors hypothesized that the causative gene may be located at 
or distal to 18q21.3, and that this deletion may have unveiled this autosomal recessive 
disorder. Indeed, KDSR is located at 18q21.33, and thus we speculate that loss of KDSR may 
have been responsible for this individual’s phenotype. The vast majority of cases of 
harlequin ichthyosis have bialleleic mutations in the lipid transporter gene, ABCA12 
(Akiyama, 2014), but this previous report (Stewart et al., 2001), and our current findings in 
two further subjects with harlequin ichthyosis, identify KDSR as a possible additional 
candidate gene for non-ABCA12 harlequin ichthyosis. 
The mutations we identified in KDSR are predominantly loss-of-function, leading to 
reduced ceramide synthesis with a relative reduction of esterified ceramides evident in our 
tape stripping and liquid chromatography-mass spectrometry analyses. Ceramides are a 
class of sphingolipids, a family of lipids present in eukaryotes, which are involved in a variety 
of key physiologic functions in the skin, brain, immune system, and blood vessels (Wegner 
et al., 2016). Ceramides are vital not only for membrane structure integrity but are also 
essential for critical signaling processes such as cell cycle arrest, migration, chemotaxis, 
adhesion, and differentiation (Wegner et al., 2016). Additionally, ceramides are relevant to 
proliferation, inflammation, apoptosis, and autophagy in the context of stress (Uchida, 
2014). There are more than 1,000 ceramide species, of which the majority is present in skin 
stratum corneum (Kihara, 2016). The major route of ceramide formation is the salvage 
pathway, which delivers 50-90 % of the ceramide, and uses hydrolysis of sphingomyelin by 
sphingomyelinase (Linn et al., 2001). Ceramide can be also synthesized de novo in the 
endoplasmic reticulum (Linn et al., 2001). The first step in the de novo pathway of ceramide 
synthesis is catalyzed by serine palmitoyltransferase (SPT), condensing L-serine and a fatty 
acid (FA) to generate 3-ketodihydrosphingosine (KDS). Subsequently, reduction of 3-KDS by 
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KDSR produces dihydrosphingosine (DHS). DHS is the substrate of ceramide synthases, a 
group of six enzymes, which bind FAs of varying lengths to the amide group of DHS, thus 
giving rise to a variety of dihydroceramides (Levy and Futerman, 2010). Finally, 
dihydroceramide desaturase creates a double bond between positions 4 and 5, generating 
ceramide. 
The patients with mutations in KDSR also exhibit progressive thrombocytopenia and 
a moderate functional platelet defect that develops early in life. The most likely explanation 
for the reduction in platelet count is diminished S1P synthesis. With relevance to onset of 
platelet loss, transplacental sphingosine stored in erythrocytes during fetal life may account 
for thrombocytopenia not being evident at birth. Instead, this phenomenon may manifest 
once the release from these cells, with a life span of four months, is compromised. In 
thrombopoiesis, both extracellular and intracellular normal levels of this lipid mediator are 
essential in pro-platelet shedding from megakaryocytes in genetically deficient mice (Zhang 
et al., 2012; Zhang et al., 2013). Therefore, defects in platelet formation and release in the 
final stage of thrombopoiesis may contribute to the pathogenesis of thrombocytopenia in 
the KDSR patients. Moreover, the functional defects associated with mutations in KDSR 
could be related not only to the reduced synthesis of S1P, but also ceramide.  Previous 
studies in knockout mice have shown that platelets defective in S1P or ceramide fail to 
activate normally, and that exogenous ceramide or S1P is able to rescue the phenotype of 
defective platelet secretion and aggregation (Munzer et al., 2014; Urtz et al., 2015).  
The platelet abnormalities in the patients proved difficult to treat with conventional 
approaches but an alternative strategy might be to use drugs such as fingolimod and related 
S1P receptor targeting drugs that act as agonists upon initial binding to S1P receptor. 
Fingolimod administration causes a rapid increase in platelet numbers in mice (Zhang et al., 
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2012) suggesting that acute agonistic action of the drug on megakaryocyte S1P receptor-
induced platelet release. Thus, it could be possible, in patients with reduced but not absent 
KDSR enzymatic activity, to therapeutically regulate platelet deficiencies by targeting the 
S1P receptor. Regarding treatment of the skin, we saw no or limited response to systemic 
retinoid (acitretin) in three subjects (patients 1, 2 and 3). In contrast, use of isotretinoin in 
individuals with KDSR mutations and a progressive symmetric erythrokeratoderma 
phenotype was reported to be very effective (Boyden et al., 2017). In our study (patient 3), 
and that of Boyden et al. (2017), there were two cases that died in early infancy. Although 
there are currently no data specifically implicating KDSR mutations as being any more likely 
to lead to increased infant mortality over other forms of congenital ichthyosis, this 
potentially poor outcome will need to be reviewed as more cases of KDSR mutations are 
documented.  
In conclusion, our data add to recent findings by Boyden et al. (2017) in 
demonstrating defective ceramide biosynthesis due to mutations in KDSR is responsible for 
some forms of local hyperkeratosis and generalized ichthyosis. Moreover, we show that the 
KDSR mutations we identified are also associated with accompanying thrombocytopenia. 
Our work therefore extends knowledge about ceramides in skin disease and provides 
original insights into ceramides and platelet biology, with collective implications for patient 
diagnostics, prognostics and therapeutics.  
 
MATERIALS & METHODS 
The full description of all materials and methods used in this study for venous blood 
sampling for DNA, platelet, plasma and serum studies, as well as methodology for WES 
(including reads and coverage), cell culture and transfection, immunofluorescence 
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microscopy, qPCR, and platelet microscopy and flow cytometry are provided in the 
Supplementary Materials online. 
 
Yeast strain and medium 
The yeast Saccharomyces cerevisiae strain KHY625 (MATa ura3 his3 trp1 leu2 Δtsc10::LEU2; 
Kihara and Igarashi, 2004) harboring a URA3 marker-containing plasmid was grown on 
synthetic complete minus uracil (SC-URA; 0.67% yeast nitrogen base, 2% D-glucose, 0.5% 
casamino acids, 20 mg/L adenine, and 20 mg/L tryptophan) plates with or without 5 μM 
phytosphingosine (PHS) and 0.0015% Nonidet P-400 (dispersant) at 30 °C. 
 
Plasmid generation 
Human FVT-1/KDSR cDNA was digested from the pAK591 plasmid (Kihara and Igarashi, 2004) 
and cloned into pCE-puro 3xFLAG-1, the mammalian expression vector designed for N-
terminal 3xFLAG-tagged protein production. Four of the identified mutations (F138C, Δ5, 
Δ5Δ6, and Q271E) were created using the QuikChange Site-Directed Mutagenesis Kit 
(Agilent Technologies, Santa Clara, CA) and the primers listed in Supplementary Table S1 
online. The E75Nfs*2 mutant was produced by amplifying the mutated KDSR gene using the 
primers KDSR-F and KDSR E75Nfs*2, respectively (Supplementary Table S1 online), followed 
by cloning into the pCE-puro 3xFLAG-1 vector. For expression in yeast, wild type and mutant 
KDSR plasmids were transferred into pAKNF316 (CEN, URA3 marker), the yeast expression 
vector designed to produce N-terminally 3xFLAG-tagged protein under the control of a 
glyceraldehyde 3-phosphate dehydrogenase (GAPDH) promoter. 
 
Immunoblotting 
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Immunoblotting was performed as described previously (Kitamura et al., 2015) using anti-
FLAG M2 antibody (1.85 μg/mL; Sigma, St. Louis, MO) as the primary antibody and an HRP-
conjugated anti-mouse IgG F(ab′)2 fragment (diluted 1:7500; GE Healthcare Life Sciences, 
Piscataway, NJ) as the secondary antibody. 
 
In vitro 3-ketodihyrosphingosine (KDS) reductase assay 
Cells were suspended in buffer A [50 mM Tris-HCl (pH 7.5), 10% glycerol, 150 mM NaCl, 1 
mM EDTA, 1× protease inhibitor mixture (Complete
TM
 EDTA free; Roche Diagnostics, Basel, 
Switzerland), 1 mM PMSF, and 1 mM DTT] and lysed by sonication. After ultracentrifugation 
(100,000 × g, 30 min, 4 °C), the pellet was suspended in buffer A and was used as the total 
membrane fraction. Protein amounts were quantified using the Pierce BCA Protein Assay Kit 
(Thermo Fisher Scientific, Waltham, MA). In vitro KDS reductase assay was performed by 
incubating the total membrane fraction (1 μg) with 1 mM NADPH and 10 μM KDS (C18, 
Matreya LCC, PA, USA) at 37 °C for 1 h. Lipids were extracted by mixing with successive 
additions of 3.75 volume of chloroform/methanol/HCl (100:200:1, vol/vol/vol), 1.25 volume 
of chloroform, and 1.25 volume of water. Phases were separated by centrifugation (20,000 
× g, room temperature, 3 min). The resulting organic (lower) phase was recovered, dried, 
and dissolved in methanol. The reaction product dihydrosphingosine (DHS) was detected by 
ultra performance liquid chromatography (UPLC) coupled with electrospray ionization (ESI) 
tandem triple quadrupole MS (Xevo TQ-S; Waters, Milford, MA). The UPLC solvent systems 
and ESI condition were described previously (Yamamoto et al., 2016). DHS was detected by 
multiple reaction monitoring by selecting the m/z value of 302.2 at Q1 and the m/z value of 
266.0 at Q3 with the collision energy setting at 20 V in positive ion mode (Supplementary 
Table S5 online). DHS levels were quantified using a standard curve plotted from serial 
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dilutions of DHS (Avanti Polar Lipids, Alabaster, AL) standard. Data were analyzed using 
MassLynx software (Waters). 
 
Tape stripping for ceramide analysis 
To examine the ceramide species present in the stratum corneum, tape stripping was 
performed by pressing an acryl film tape (456#40, Teraoka Seisakusho, Tokyo, Japan) to the 
skin of the forearm, wrist and palm. Five strips measuring 25 mm x 50 mm each were 
obtained from a single individual. The samples were then subjected to liquid 
chromatography-mass spectrometry (LC-MS) analysis to assess the levels of 11 major 
ceramide species (Ohno et al., 2015). The strips were cut into two half-strips, one for lipid 
analysis, and the other for protein analysis. The lipids within the first half-strip were 
dissolved in 2mL of chloroform/methanol/2-propanol (10:45:45, vol/vol/vol). N-
Heptadecanoyl-D-erythro-Sphingosine (d18:1/17:0) (Avanti Polar Lipids) was added as an 
internal control, and its final concentration was 50 nM. This lipid solution was subjected to 
reversed-phase LC/MS. The system was Agilent 1100 Series LC/MSD SL system equipped 
with a multi-ion source, ChemStation software, a 1,100-well plate auto-sampler (Agilent 
Technologies) and an L-column ODS (2.1 mm i.d. x 150 mm; Chemicals Evaluation and 
Research Institute). Chromatographic separation of the lipids was achieved at a flow rate of 
0.2 mL/min using a mobile phase of binary gradient solvent system. Each ceramide species 
was detected by selected ion monitoring of m/z [M+CH3COO]−. Soluble proteins were 
extracted from the other half-strip with a 0.1 M NaOH of 1% sodium dodecyl sulfate 
aqueous solution, at 60°C for 150 min. The extract solutions were then neutralized with an 
HCl aqueous solution. After that, soluble proteins were measured using a BCA protein assay 
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kit (Thermo Fisher Scientific, Waltham, MA, USA). Samples were taken from two 
unaffected mothers (Families 1 and 2) as a control. 
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FIGURE LEGENDS 
Figure 1. Pedigrees and mutations identified in KDSR. (a-d) Family pedigrees of the four 
patients with compound heterozygous mutations in KDSR. ‘+’ denotes the wild-type allele; 
(e) Schematic of KDSR to show the six compound heterozygous mutations identified in this 
study. 
 
Figure 2. Clinicopathologic features of Patient 1. (a) diffuse palmar keratoderma; (b) 
perianal hyperkeratosis; (c) bilateral diffuse plantar keratoderma; (d) light microscopy of 
palmar skin shows psoriasiform acanthosis and hyperkeratosis (H&E stain; bar = 100 µm); 
higher magnification reveals focal hypergranulosis and parakeratosis (H&E stain; bar = 10 
µm). 
 
Figure 3. Mutations in KDSR impair enzymatic activity in vitro. (a) Total lysates prepared 
from KHY625 (Δtsc10) cells harboring an empty vector or the plasmid encoding wild-type 
(WT) or mutant 3xFLAG-KDSR were separated by SDS-PAGE and subjected to 
immunoblotting using anti-FLAG M2 antibody. (b) KHY625 cells bearing the indicated 
plasmid were grown serially diluted at 1:10, spotted on SC-URA plates with or without 5 μM 
PHS, and grown at 30°C for 3 days. (c and d) HEK 293T cells were transfected with an empty 
vector or the plasmid encoding WT or mutant 3xFLAG-KDSR. DHS-levels in the membrane 
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fractions from the cells transfected with empty vector are due to activity of endogenous 
KDSR. Twenty-four hours after transfection, total membrane fractions were prepared. (c) 
Total membrane fractions (5 μg protein) were separated by SDS-PAGE and subjected to 
immunoblotting using anti-FLAG M2 antibody. (d) Total membrane fractions were incubated 
with 10 μM KDS and 1 mM NADPH at 37 °C for 1 h. Lipids were extracted and subjected to 
LC-MS/MS analysis. DHS was detected in the MRM mode and quantified using MassLynx 
software. Values represent the mean ± SDs of three independent experiments. Statistically 
significant differences compared to WT are indicated. **P<0.01; Tukey’s Test.  
 
 
Figure 4. Tape stripping and liquid chromatography-mass spectrometry analysis reveals 
reduced percentages of esterified ceramides in patient 1 and 2 skin. (a) In palm skin total 
ceramide levels in patient 1 are reduced in comparison to his mother although differences  
are not observed in patient 2 with a milder clinical phenotype; (b) total ceramide levels are 
also reduced in wrist skin in both patients with respect to their mothers, more so for patient 
1; (c) in forearm skin (clinically normal) total ceramide levels are not reduced in patient skin; 
(d) sub-analysis of the relative percentages of esterified and non-esterified ceramides 
reveals reduced levels of esterified ceramides for all patient samples compared to their 
respective mothers with the exception of the palm sample from the mother of patient 2. A 
more detailed analysis of these data are presented in Supplementary Tables S4 and S5 
online.  
 
Figure 5. Functional differences are present in platelets from patients 1 and 2 compared to 
control. Platelets from compound heterozygotes of the mutations c.413T>G and 
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c.417+3A>C in KDSR, their heterozygous mothers (carrying the c.417+3A>C mutation), and 
healthy unrelated controls (combined data from two subjects), were stimulated under static 
conditions (30 min at RT) with agonist (1.6 mM arachidonic acid [AA], 10 μM adenosine 
diphosphate [ADP], 25 μM PAR1 peptide [PAR1p], 100 μM PAR4 peptide [PAR4p], 2 μg/mL 
convulxin [CVX], and 2 μg/mL collagen-related-peptide [CRP] in the presence of both PAC-1-
FITC and anti-CD62P-PE monoclonal antibodies. The samples were evaluated by flow 
cytometry and the median fluorescence intensity [MFI]) for alpha granule release (anti-
CD62P-PE, panel a) and αIIbβ3 integrin activation (anti PAC-1-FITC, panel b) is shown. Values 
presented are the mean of median fluorescence intensity (MFI) ± standard error of mean 
(SEM) in duplicate samples from the two compound heterozygote patients (black bars), 
their mothers (white bars) and two parallel controls (gray bars); *indicates significant 
differences (p<0.05; Mann-Whitney test) compared to controls. 
 
Figure 6. KDSR mutations reduce sphingosine 1 phosphate (S1P) and ceramide expression 
in plasma, serum and activated platelets. (a) S1P concentration in blood plasma and serum 
samples obtained from Patients 1 and 2, and normal subjects. Red bars represent the 
affected individuals, and green bars two parallel controls. (b) Ceramide expression in 
stimulated platelets in response to 250 mM PAR1p. Bars colored in lighter shades of red, 
blue, and green represent unstimulated cells and the bars in darker shades of each 
respective color indicate activated platelets. The values shown are the means of duplicate 
samples of (a) S1P concentration and (b) median fluorescence intensity (MFI). The error bars 
indicate the SEM. *denotes significant differences (p<0.05; Mann-Whitney test) in plasma 
S1P levels between patients and normal subjects (a), and in ceramide expression between 
unstimulated and activated platelets (b). 
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TABLES 
Patient Country 
of origin 
Dermatologic 
phenotype 
Thrombocytopenia Mutations in KDSR & 
amino acid change 
1000 
Genomes 
Project 
frequency 
ExAC 
frequency 
SIFT 
(score) 
PolyPhen-
2 (score) 
Mutation 
Taster 
1 Spain Palmoplantar 
and perianal 
keratoderma 
+ c.413T>G: p.Phe138Cys 
 
0 8.3 x 10
-5
 Damaging Probably 
damaging 
Disease-
causing 
c.417+3A>C 0 0 N/A N/A Disease-
causing 
2 Spain Palmoplantar 
and perianal 
keratoderma 
+ c.413T>G: p.Phe138Cys 
 
0 8.3 x 10
-5
 Damaging Probably 
damaging 
Disease-
causing 
c.417+3A>C 0 0 N/A N/A Disease-
causing 
3 United 
Kingdom 
Harlequin 
ichthyosis 
+ c.812G>A: p.Gly271Glu 
 
0 0 Damaging Probably 
damaging 
Disease-
causing 
c.879G>A: p.Gln293Gln 0 3.3 x 10
-5
 N/A N/A Disease-
causing 
4 Japan Harlequin 
ichthyosis 
+ c.223_224delGA: 
p.Glu75Asnfs*2 
 
0 0 N/A N/A Disease-
causing 
c.544G>A: p.Gly182Ser 0 8.2 x 10
-6
 Damaging Probably 
damaging 
Disease-
causing 
 
Table 1. Summary of clinical and mutation details of all four affected individuals. 
 
 P1 P2 Mother of P1 Mother of P2 Control 1 Control 2 
WBC (x10
9
/L) 16.1 8.2 5.2 8.6 7.2 7.8 
Hb (g/dL) 13.9 12.7 12.4 13.5 12.8 14.3 
Ht (%) 40.2 37.9 36.6 39.9 37.7 42.6 
Platelets (x10
9
/L) 24 7 213 226 207 206 
FSC (MFI) 32.9 32.9 26.8 27.9 25.7 25.6 
CD42b (MFI) 127.2 122.8 152.7 186.2 161.3 199.5 
CD42a (MFI) 187.2 189.2 188.1 207.7 180.6 212.8 
CD61 (MFI) 209.8 215.3 194.5 237.8 216.7 226.4 
CD49b (MFI) 29.5 28.5 33.6 41.1 39.5 31.6 
Annexin V (% positive) 2.5 1.7 5.9 4.2 4.7 3.6 
Tissue factor (% 
positive) 
4.2 4.4 7.8 5.9 7.5 6.2 
 
Table 2. Blood parameters, platelet size, glycoprotein expression, and annexin V and 
tissue factor binding in Patients 1 and 2, their mothers, and normal controls. WBC: white 
blood cells; RBC: red blood cells; Hb: hemoglobin; Ht: hematocrit; FSC: Forward side scatter; 
MFI: median fluorescence intensity; P1: Patient 1; P2: Patient 2. 
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